ITEK Inotek Pharmaceuticals Corporation

2.36
-0.09  -4%
Previous Close 2.45
Open 2.48
Price To book 1.26
Market Cap 64245678
Shares 27,222,745
Volume 214,516
Short Ratio 1.07
Av. Daily Volume 1,727,023

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 trial failed - noted July 7, 2017.
Trabodenoson and latanoprost
Glaucoma

Latest News

  1. Inotek Pharmaceuticals: Upcoming Merger with Rocket and New Pipeline
  2. New Research: Key Drivers of Growth for Antares Pharma, Infinity Pharma, Inotek Pharma, Hostess Brands, Arconic, and Enterprise Products - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production
  3. Today's Research Reports on Stocks to Watch: Inotek Pharmaceuticals and Aurinia Pharmaceuticals
  4. Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket Pharmaceuticals
  5. Is It The Right Time To Buy Inotek Pharmaceuticals Corporation (ITEK)?
  6. Today's Research Reports on Stocks to Watch: Inotek Pharmaceuticals and 22nd Century Group
  7. INSERTING and REPLACING Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases
  8. Inotek Pharmaceuticals reports 2Q loss
  9. Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights
  10. Featured Company News – Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update
  11. Today's Research Reports on Stocks to Watch: Ocular Therapeutix and Inotek Pharmaceuticals
  12. Inotek to consider strategic options after eye drug fails another study
  13. Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update
  14. Options Traders Expect Huge Moves in Inotek Pharmaceuticals (ITEK) Stock
  15. Inotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights
  16. Inotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting
  17. Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma